Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Kenneth C. Anderson, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Kraft Family Professor of Medicine, Harvard Medical School
  • Program Director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics

Centers/Programs

Clinical Interests

  • Multiple myeloma
  • Stem cell/ bone marrow transplant

Diseases Treated

Contact Information

  • Appointments617-632-3823 (new)
    617-582-8347 (follow-up)
  • Office Phone Number617-632-2144
  • Fax617-632-2140

Bio

Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School as well as Director of the LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. He is a Doris Duke Distinguished Clinical Research Scientist and American Cancer Society Clinical Research Professor. After graduating from Johns Hopkins Medical School, he trained in internal medicine at Johns Hopkins Hospital, and then completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Over the last four decades, he has focused his laboratory and clinical research studies on multiple myeloma. He has developed laboratory and animal models of the tumor in its microenvironment which have allowed for both identification of novel targets and validation of novel targeted therapies, and has then rapidly translated these studies to clinical trials culminating in FDA approval of novel targeted and immune therapies. His paradigm for identifying and validating targets in the tumor cell and its milieu has transformed myeloma therapy and markedly improved patient outcome.

Board Certification:

  • Internal Medicine, 1980

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology

Residency:

  • Johns Hopkins School of Medicine, Internal Medicine

Medical School:

  • Johns Hopkins University School of Medicine

Recent Awards:

  • Robert A. Kyle Lifetime Achievement Award 2005
  • Doris Duke Distinguished Clinical Research Scientist
  • American Cancer Society Clinical Research Professor
  • The International Myeloma Workshop Waldenstrom’s Award
  • International Myeloma Foundation Robert A. Kyle Lifetime Achievement Award
  • American Association for Cancer Research Joseph H. Burchenal Award
  • American Society of Hematology William Dameshek Prize
  • Johns Hopkins Society of Scholars
  • Election to the Institute of Medicine of the National Academy of Sciences and the Royal Colleges of Physicians and of Pathologists (UK)
  • American Society of Clinical Oncology David A. Karnofsky Award
  • Hope Funds for Cancer Research Award of Excellence in Clinical Research
  • Ron Burton Humanitarian Award
  • Harvard Medical School Warren Alpert Foundation Prize
  • American Cancer Society Medal of Honor
  • Leonard P. Zakim Patient Advocacy Award
  • Samuel Waxman Research Foundation David Workman Memorial Award
  • University of Miami Sylvester Cancer Center Annual Zubrod Memorial Award

Research

Novel Biologically Based Therapies for Multiple Myeloma
Our long-term interest is to develop models of myeloma to define genetic and molecular mechanisms of growth, survival, and drug resistance in its bone marrow milieu. Our bench-to-bedside studies have identified novel targets, validated targeted therapies, and led to the approval of novel agents that have markedly prolonged patient survival. Ongoing efforts focus on protein catabolism, tumor microenvironment, immunotherapy, clinical translation of targeted therapies, and genomics, in order toboth enhance understanding of myeloma heterogeneity and pathogenesis, as well as identify and validate next-generation novel small molecule and immune targeted therapies.  Protein Catabolism Our basic studies have defined the roles of the ubiquitin proteasomal cascade, as well as the alternative aggresomal pathway, regulating protein homeostasis in multiple myeloma.  In preclinical models, we have validated multiple agents targeting these pathways and then led clinical trials leading to their FDA approval.  Our studies of second generation proteasome inhibitors, histone deacetylase inhibitors, deubiquitylating enzyme inhibitors, and ubiquitin receptor inhibitors have further confirmed the therapeutic utility of targeting protein homeostasis in cancer. Tumor Microenvironment We have identified and characterized the role of adhesion molecules, extracellular matrix proteins, cytokines, and accessory cells in promoting tumor cell growth, survival, and drug resistance in the bone marrow microenvironment; and have validated therapies directed at these mechanisms. Immunomodulatory drugs have translated to clinical trials and FDA approval, and multiple first in man trials are ongoing. Immunotherapy We generated monoclonal antibodies for diagnosis and treatment of myeloma. We also defined the mechanisms and strategies to overcome immunosuppression and stimulate autologous anti-tumor immunity in myeloma including: single agents/combinations of immunomodulatory drugs, monoclonal antibodies, immunotoxins, checkpoint inhibitors, vaccines, histone deacetylase inhibitors, and cellular therapies. Clinical Translation of Novel Therapies Having validated proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies in our preclinical models of myeloma in its bone marrow microenvironment, we have translated these studies to clinical trials leading to their FDA approval and transformed the treatment paradigm.  Our preclinical mechanistic studies have informed combinations of targeted therapies, which have prolonged the survival of patients three to four fold. Genomics/Epigenomics We have utilized genomic/epigenomic profiling of patient myeloma samples to: characterize disease pathogenesis; improve diagnosis, prognosis, and treatment; defined disease heterogeneity and clonality; delineate mechanisms of drug resistance and disease progression; and inform novel therapies for subsets of patients with myeloma.



ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021 Jul; 2(4):338-353.
View in: PubMed

The HCK/BTK inhibitor KIN-8194 is active in MYD88 driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 Jun 16.
View in: PubMed

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 Jun; 7(23).
View in: PubMed

Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Cancer Discov. 2021 Jul; 2(4):370-387.
View in: PubMed

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 Apr 08; 137(14):1905-1919.
View in: PubMed

Facts and Hopes in Multiple Myeloma Immunotherapy. Clin Cancer Res. 2021 Mar 26.
View in: PubMed

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 Mar 16.
View in: PubMed

Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov. 2021 Mar; 2(2):119-124.
View in: PubMed

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
View in: PubMed

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
View in: PubMed

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol. 2020; 10:606368.
View in: PubMed

Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity. Leukemia. 2021 Jan 24.
View in: PubMed

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. 2021 Jan 13; 11(1):13.
View in: PubMed

Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers (Basel). 2021 Jan 08; 13(2).
View in: PubMed

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040.
View in: PubMed

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 Mar 01; 39(7):757-767.
View in: PubMed

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999.
View in: PubMed

Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723.
View in: PubMed

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020 11 12; 136(20):2334-2345.
View in: PubMed

Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06.
View in: PubMed

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110.
View in: PubMed

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 11; 191(3):442-452.
View in: PubMed

Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther. 2020; 9:201-215.
View in: PubMed

Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 10 01; 105(10):2358-2367.
View in: PubMed

Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020 Nov; 1(3):258-273.
View in: PubMed

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 09 08; 4(17):4195-4207.
View in: PubMed

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91.
View in: PubMed

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.
View in: PubMed

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol. 2020; 11:1771.
View in: PubMed

Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 Jul 23.
View in: PubMed

YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
View in: PubMed

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
View in: PubMed

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2021 03; 35(3):752-763.
View in: PubMed

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971.
View in: PubMed

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in: PubMed

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. Eur J Haematol. 2020 Sep; 105(3):326-334.
View in: PubMed

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel). 2020 Jun 05; 12(6).
View in: PubMed

Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e652-e659.
View in: PubMed

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
View in: PubMed

Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2021 02; 35(2):550-561.
View in: PubMed

Timing the initiation of multiple myeloma. Nat Commun. 2020 04 21; 11(1):1917.
View in: PubMed

Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. 2020 07; 18(7):1063-1073.
View in: PubMed

Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant. 2020 08; 26(8):1414-1424.
View in: PubMed

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2021 01; 35(1):177-188.
View in: PubMed

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
View in: PubMed

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May; 7(5):e395-e407.
View in: PubMed

Changing the Paradigm. Oncology (Williston Park). 2020 Mar 19; 34(3).
View in: PubMed

Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044.
View in: PubMed

The safety of current and emerging therapies for multiple myeloma. Expert Opin Drug Saf. 2020 Mar; 19(3):269-279.
View in: PubMed

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 08; 34(8):2150-2162.
View in: PubMed

Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene. 2020 03; 39(13):2786-2796.
View in: PubMed

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 01 14; 4(1):181-190.
View in: PubMed

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 2019 11 26; 8(12).
View in: PubMed

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 12 07; 394(10214):2096-2107.
View in: PubMed

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 11 12; 3(21):3248-3260.
View in: PubMed

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):344-353.
View in: PubMed

The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019 10 08; 3(19):2895-2904.
View in: PubMed

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
View in: PubMed

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2020 02; 34(2):567-577.
View in: PubMed

Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835.
View in: PubMed

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223.
View in: PubMed

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity. Blood Cancer J. 2019 08 12; 9(8):64.
View in: PubMed

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019 Oct; 15(28):3267-3281.
View in: PubMed

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 Aug 01; 25(15):4860.
View in: PubMed

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019 11; 19(11):1143-1156.
View in: PubMed

Insights into the management of older patients with multiple myeloma. Clin Adv Hematol Oncol. 2019 Jul; 17(7):390-392.
View in: PubMed

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020 01; 34(1):167-179.
View in: PubMed

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 06; 20(6):e302-e312.
View in: PubMed

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2020 01; 34(1):196-209.
View in: PubMed

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 06; 20(6):781-794.
View in: PubMed

Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clin Cancer Res. 2019 May 01; 25(9):2938.
View in: PubMed

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. 2019 11; 33(11):2685-2694.
View in: PubMed

Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
View in: PubMed

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 07 11; 134(2):123-133.
View in: PubMed

Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
View in: PubMed

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
View in: PubMed

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):372-380.
View in: PubMed

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019 01 09; 11(1).
View in: PubMed

Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J. 2019 Jan/Feb; 25(1):11-18.
View in: PubMed

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6.
View in: PubMed

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med. 2018 Dec; 6(Suppl 2):S93.
View in: PubMed

PRMT5 inhibitors on the (myeloma) road. Oncotarget. 2018 Nov 30; 9(94):36646-36647.
View in: PubMed

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):88-96.
View in: PubMed

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):83-87.
View in: PubMed

The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
View in: PubMed

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
View in: PubMed

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109.
View in: PubMed

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia. 2019 03; 33(3):766-771.
View in: PubMed

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
View in: PubMed

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464.
View in: PubMed

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377.
View in: PubMed

The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018 08 22; 8(9):83.
View in: PubMed

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
View in: PubMed

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clin Cancer Res. 2018 12 15; 24(24):6570-6582.
View in: PubMed

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol. 2018; 9:1821.
View in: PubMed

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. Front Immunol. 2018; 9:1822.
View in: PubMed

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
View in: PubMed

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019 01; 33(1):171-180.
View in: PubMed

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170.
View in: PubMed

Promise of Immune Therapies in Multiple Myeloma. J Oncol Pract. 2018 07; 14(7):411-413.
View in: PubMed

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
View in: PubMed

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018 08; 182(4):495-503.
View in: PubMed

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616.
View in: PubMed

Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 08; 103(8):1380-1389.
View in: PubMed

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446.
View in: PubMed

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
View in: PubMed

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
View in: PubMed

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
View in: PubMed

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018 05 15; 78(10):2747-2759.
View in: PubMed

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2018 04; 14(4):266-269.
View in: PubMed

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
View in: PubMed

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Ann Hematol. 2018 May; 97(5):839-849.
View in: PubMed

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 03 10; 36(8):812-818.
View in: PubMed

The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018 04; 15(4):219-233.
View in: PubMed

Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget. 2017 Dec 22; 8(68):112166-112167.
View in: PubMed

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018 May; 14(11):1035-1047.
View in: PubMed

The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 12; 36(4):561-584.
View in: PubMed

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opin Pharmacother. 2017 Dec; 18(18):1975-1985.
View in: PubMed

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2018 02; 14(2):129-133.
View in: PubMed

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 01 20; 36(3):283-299.
View in: PubMed

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 01 18; 131(3):301-310.
View in: PubMed

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies (Basel). 2017 Nov 14; 6(4).
View in: PubMed

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem Biol. 2017 12 21; 24(12):1490-1500.e11.
View in: PubMed

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017 12; 179(5):756-771.
View in: PubMed

Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
View in: PubMed

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
View in: PubMed

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget. 2017 Sep 19; 8(41):69237-69249.
View in: PubMed

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3279-3289.
View in: PubMed

Multiple myeloma. Nat Rev Dis Primers. 2017 Jul 20; 3:17046.
View in: PubMed

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era. Exp Hematol Oncol. 2017; 6:20.
View in: PubMed

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918.
View in: PubMed

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Oct 06; 8(46):80109-80123.
View in: PubMed

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep; 178(6):896-905.
View in: PubMed

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Jul 05.
View in: PubMed

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.
View in: PubMed

MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
View in: PubMed

Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma. 2018 03; 59(3):542-561.
View in: PubMed

Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Sep 12; 8(39):66641-66655.
View in: PubMed

Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 08.
View in: PubMed

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 08; 178(4):547-560.
View in: PubMed

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
View in: PubMed

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 01; 23(15):3980-3993.
View in: PubMed

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320.
View in: PubMed

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224.
View in: PubMed

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.
View in: PubMed

Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv. 2017 Mar 14; 1(8):517-521.
View in: PubMed

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289.
View in: PubMed

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. 2017 Aug 01; 23(15):4290-4300.
View in: PubMed

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
View in: PubMed

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
View in: PubMed

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
View in: PubMed

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35.
View in: PubMed

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
View in: PubMed

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
View in: PubMed

Progress and Paradigms in Multiple Myeloma. Clin Cancer Res. 2016 Nov 15; 22(22):5419-5427.
View in: PubMed

Immune Therapies in Multiple Myeloma. Clin Cancer Res. 2016 Nov 15; 22(22):5453-5460.
View in: PubMed

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13162-13167.
View in: PubMed

AACR Cancer Progress Report 2016: Improving Lives Through Research. Clin Cancer Res. 2016 10 01; 22(19):4759.
View in: PubMed

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618.
View in: PubMed

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.
View in: PubMed

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J Exp Med. 2016 08 22; 213(9):1705-22.
View in: PubMed

A new era of immune therapy in multiple myeloma. Blood. 2016 07 21; 128(3):318-9.
View in: PubMed

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016 09 22; 128(12):1590-603.
View in: PubMed

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
View in: PubMed

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695.
View in: PubMed

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109.
View in: PubMed

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52.
View in: PubMed

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther. 2016 06; 15(6):1364-75.
View in: PubMed

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016 Sep; 174(5):711-20.
View in: PubMed

NCCN Guidelines Update for Multiple Myeloma. J Natl Compr Canc Netw. 2016 05; 14(5 Suppl):675-7.
View in: PubMed

The Rapid Evolution of Novel Therapies in Multiple Myeloma. J Natl Compr Canc Netw. 2016 05; 14(5):493-6.
View in: PubMed

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
View in: PubMed

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016 Sep; 104(3):300-9.
View in: PubMed

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016 08; 174(3):397-409.
View in: PubMed

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400.
View in: PubMed

Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016 Mar 28.
View in: PubMed

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700.
View in: PubMed

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
View in: PubMed

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; 127(24):2955-62.
View in: PubMed

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):329-334.e1.
View in: PubMed

MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
View in: PubMed

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016 Apr; 173(1):82-8.
View in: PubMed

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
View in: PubMed

Vision Statement for Multiple Myeloma: Future Directions. Cancer Treat Res. 2016; 169:15-22.
View in: PubMed

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
View in: PubMed

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
View in: PubMed

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84.
View in: PubMed

Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
View in: PubMed

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27.
View in: PubMed

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016 Mar 01; 22(5):1222-33.
View in: PubMed

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435.
View in: PubMed

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015 Dec; 171(5):798-812.
View in: PubMed

AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine. Clin Cancer Res. 2015 Oct 01; 21(19):4247.
View in: PubMed

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051.
View in: PubMed

Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015; 7(11):1187-99.
View in: PubMed

Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015 Oct 15; 75(20):4384-4397.
View in: PubMed

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9.
View in: PubMed

Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015 Aug; 43(8):732-41.
View in: PubMed

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015 Sep; 5(9):972-87.
View in: PubMed

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13; 373(7):621-31.
View in: PubMed

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
View in: PubMed

Promising therapies in multiple myeloma. Blood. 2015 Jul 16; 126(3):300-10.
View in: PubMed

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
View in: PubMed

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
View in: PubMed

Multiple myeloma: new uses for available agents, excitement for the future. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):694-6.
View in: PubMed

Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2).
View in: PubMed

Novel therapeutic targets in multiple myeloma. Clin Adv Hematol Oncol. 2015 Apr; 13(4):236-48.
View in: PubMed

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
View in: PubMed

CCR 20th anniversary commentary: In the beginning, there was PS-341. Clin Cancer Res. 2015 Mar 01; 21(5):939-41.
View in: PubMed

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr; 90(4):314-9.
View in: PubMed

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015 May 01; 21(9):2148-56.
View in: PubMed

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 03 26; 125(13):2068-74.
View in: PubMed

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015 Feb 20; 33(6):657-64.
View in: PubMed

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015; 11(8):1153-68.
View in: PubMed

Clinical Cancer Research: the 20th anniversary. Clin Cancer Res. 2015 Jan 01; 21(1):3.
View in: PubMed

Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015 Jan; 263(1):160-72.
View in: PubMed

Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914.
View in: PubMed

Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015 Jan; 12(1):42-54.
View in: PubMed

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
View in: PubMed

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12):e538-48.
View in: PubMed

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17; 15:904.
View in: PubMed

Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. J Control Release. 2014 Dec 28; 196:113-21.
View in: PubMed

Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):927-43.
View in: PubMed

Multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):xi-xii.
View in: PubMed

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035.
View in: PubMed

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014 Nov-Dec; 64(6):422-44.
View in: PubMed

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan; 100(1):100-6.
View in: PubMed

Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
View in: PubMed

AACR cancer progress report 2014: transforming lives through research. Clin Cancer Res. 2014 Oct 01; 20(19):4977.
View in: PubMed

Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86.
View in: PubMed

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 04; 371(10):906-17.
View in: PubMed

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. . 2014 Nov; 13(11):2489-500.
View in: PubMed

Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):903-25.
View in: PubMed

The challenge of cross-trial comparisons using limited data. Haematologica. 2014 Aug; 99(8):e145-6.
View in: PubMed

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
View in: PubMed

Looking forward: an update to the CCR instructions for authors. Clin Cancer Res. 2014 Jul 15; 20(14):3629.
View in: PubMed

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
View in: PubMed

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69.
View in: PubMed

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):356-69.
View in: PubMed

Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 Jul 10; 32(20):2125-32.
View in: PubMed

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014 Jun; 20(6):599-606.
View in: PubMed

Multiple myeloma: advances reported in 2013 are useful in the clinic. J Natl Compr Canc Netw. 2014 May; 12(5 Suppl):808-11.
View in: PubMed

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
View in: PubMed

A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. Anal Chem. 2014 Apr 01; 86(7):3667-75.
View in: PubMed

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81.
View in: PubMed

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13.
View in: PubMed

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38.
View in: PubMed

Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014 Apr; 23(4):445-52.
View in: PubMed

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar; 15(3):333-42.
View in: PubMed

IKKß inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol. 2014 Apr; 44(4):1171-6.
View in: PubMed

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
View in: PubMed

Reply to M. Roschewski et al. J Clin Oncol. 2014 Feb 10; 32(5):478.
View in: PubMed

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20; 32(6):587-600.
View in: PubMed

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.
View in: PubMed

The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014 Jan; 28(1):45-53.
View in: PubMed

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.
View in: PubMed

Future agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):127-41.
View in: PubMed

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30; 123(5):632-9.
View in: PubMed

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30; 123(5):706-16.
View in: PubMed

Announcing the AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20):5545.
View in: PubMed

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation. Cancer Lett. 2014 Feb 28; 343(2):286-94.
View in: PubMed

Clinical translation in multiple myeloma: from bench to bedside. Semin Oncol. 2013 Oct; 40(5):549-53.
View in: PubMed

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48.
View in: PubMed

Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
View in: PubMed

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct; 14(11):1129-1140.
View in: PubMed

AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20 Suppl):S4-98.
View in: PubMed

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10; 31(29):3696-703.
View in: PubMed

Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51.
View in: PubMed

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1615-24.
View in: PubMed

IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. Oncology (Williston Park). 2013 Aug; 27(8):803-4, 806.
View in: PubMed

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013 Aug 15; 122(7):1222-32.
View in: PubMed

Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
View in: PubMed

Minimal residual disease in multiple myeloma. J Clin Oncol. 2013 Jul 10; 31(20):2523-6.
View in: PubMed

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
View in: PubMed

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. Br J Haematol. 2013 Jul; 162(2):210-20.
View in: PubMed

Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw. 2013 May; 11(5 Suppl):676-9.
View in: PubMed

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 May; 71(5):1357-68.
View in: PubMed

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31.
View in: PubMed

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
View in: PubMed

Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3.
View in: PubMed

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013 Apr; 123(4):1542-55.
View in: PubMed

Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun; 19(6):858-9.
View in: PubMed

New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44.
View in: PubMed

Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol. 2013 Mar; 97(3):324-32.
View in: PubMed

Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy. 2013 Mar; 9(3):410-2.
View in: PubMed

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 15; 19(8):2096-106.
View in: PubMed

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013 Jan 31; 121(5):858.
View in: PubMed

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013 Apr; 53(2):487-96.
View in: PubMed

MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8.
View in: PubMed

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
View in: PubMed

Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6.
View in: PubMed

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
View in: PubMed

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
View in: PubMed

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013; 19(4):734-44.
View in: PubMed

Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7.
View in: PubMed

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
View in: PubMed

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
View in: PubMed

Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 01; 31(4):448-55.
View in: PubMed

New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
View in: PubMed

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
View in: PubMed

Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012 Dec 13; 120(25):4929-37.
View in: PubMed

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012 Nov 15; 18(22):6260-70.
View in: PubMed

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9.
View in: PubMed

Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov 29; 120(23):4513-6.
View in: PubMed

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 08; 120(19):3958-67.
View in: PubMed

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
View in: PubMed

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.
View in: PubMed

Gauging progress in a decades-old fight. Clin Cancer Res. 2012 Nov 01; 18(21):5833.
View in: PubMed

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
View in: PubMed

Bruton's tyrosine kinase: oncotarget in myeloma. Oncotarget. 2012 Sep; 3(9):913-4.
View in: PubMed

Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
View in: PubMed

Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
View in: PubMed

How I treat plasma cell leukemia. Blood. 2012 Sep 20; 120(12):2376-89.
View in: PubMed

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13.
View in: PubMed

Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 Sep 01; 18(17):4669-81.
View in: PubMed

Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60.
View in: PubMed

Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. Semin Hematol. 2012 Jul; 49(3):223-7.
View in: PubMed

Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target? J Natl Cancer Inst. 2012 Jul 03; 104(13):964-5.
View in: PubMed

Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
View in: PubMed

Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. J Clin Oncol. 2012 Jul 10; 30(20):e175-9.
View in: PubMed

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
View in: PubMed

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80.
View in: PubMed

Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
View in: PubMed

Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33.
View in: PubMed

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012 Jun; 157(6):687-701.
View in: PubMed

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31.
View in: PubMed

Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81.
View in: PubMed

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. . 2012 Jul; 11(7):1432-42.
View in: PubMed

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
View in: PubMed

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3.
View in: PubMed

Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
View in: PubMed

Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
View in: PubMed

The International Myeloma Society comes of age. Clin Lymphoma Myeloma Leuk. 2012 Feb; 12(1):1.
View in: PubMed

Overview of the AACR Clinical and Translational Cancer Research Think Tank meeting. Clin Cancer Res. 2012 Feb 01; 18(3):607-11.
View in: PubMed

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
View in: PubMed

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5.
View in: PubMed

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in: PubMed

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012 Mar 15; 119(11):2579-89.
View in: PubMed

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 01; 119(9):2074-82.
View in: PubMed

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. . 2012 Apr; 11(4):942-51.
View in: PubMed

The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012 Feb 01; 30(4):445-52.
View in: PubMed

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
View in: PubMed

The future of treatment for patients with relapsed/refractory multiple myeloma. Oncology (Williston Park). 2011 Nov 15; 25 Suppl 2:2.
View in: PubMed

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. . 2011 Nov; 10(11):2034-42.
View in: PubMed

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas. BMC Biol. 2011 Oct 28; 9:72.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

Disentangling the myeloma web. Clin Cancer Res. 2011 Dec 01; 17(23):7210-2.
View in: PubMed

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
View in: PubMed

Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy. 2011 Oct; 3(10):1253-64.
View in: PubMed

Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
View in: PubMed

Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
View in: PubMed

Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol. 2011 Dec; 155(5):588-98.
View in: PubMed

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011 Nov; 155(4):438-48.
View in: PubMed

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61.
View in: PubMed

BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
View in: PubMed

Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011 Oct; 94(4):344-354.
View in: PubMed

Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9.
View in: PubMed

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15.
View in: PubMed

Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011 Sep; 154(6):745-54.
View in: PubMed

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
View in: PubMed

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011; 6(7):e20226.
View in: PubMed

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15; 17(16):5311-21.
View in: PubMed

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica. 2011 Aug; 96(8):1170-9.
View in: PubMed

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
View in: PubMed

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
View in: PubMed

CCR1 as a target for multiple myeloma. Expert Opin Ther Targets. 2011 Sep; 15(9):1037-47.
View in: PubMed

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.
View in: PubMed

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40.
View in: PubMed

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
View in: PubMed

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011 May 26; 117(21):5692-700.
View in: PubMed

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73.
View in: PubMed

Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
View in: PubMed

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71.
View in: PubMed

Hematology: Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol. 2011 May; 8(5):255-6.
View in: PubMed

Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res. 2011 Mar 15; 17(6):1225-33.
View in: PubMed

Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Apr; 153(2):212-21.
View in: PubMed

Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011; 2011:924058.
View in: PubMed

A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402.
View in: PubMed

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
View in: PubMed

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
View in: PubMed

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700.
View in: PubMed

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5.
View in: PubMed

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.
View in: PubMed

Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):17-22.
View in: PubMed

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
View in: PubMed

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
View in: PubMed

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
View in: PubMed

New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program. 2011; 2011:184-90.
View in: PubMed

Multiple myeloma. Annu Rev Med. 2011; 62:249-64.
View in: PubMed

Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6:249-74.
View in: PubMed

Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011 Jan-Feb; 16(1):011006.
View in: PubMed

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011 Feb 01; 186(3):1840-8.
View in: PubMed

Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta. 2011 Mar 18; 412(7-8):562-8.
View in: PubMed

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011 Jan; 152(2):155-63.
View in: PubMed

Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol. 2011 Jan; 86(1):1-15.
View in: PubMed

Multiple myeloma: biology of the disease. Blood Rev. 2010 Nov; 24 Suppl 1:S5-11.
View in: PubMed

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
View in: PubMed

MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20.
View in: PubMed

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84.
View in: PubMed

Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010 Oct; 51(10):1779-92.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
View in: PubMed

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 02; 116(23):4906-15.
View in: PubMed

What can CCR do for you? Clin Cancer Res. 2010 Aug 15; 16(16):4069-70.
View in: PubMed

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
View in: PubMed

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
View in: PubMed

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45.
View in: PubMed

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
View in: PubMed

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010 Jun 15; 16(12):3260-9.
View in: PubMed

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8.
View in: PubMed

Kidney disease associated with plasma cell dyscrasias. Blood. 2010 Sep 02; 116(9):1397-404.
View in: PubMed

Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38.
View in: PubMed

The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
View in: PubMed

A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. . 2010 May; 9(9):1722-8.
View in: PubMed

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
View in: PubMed

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
View in: PubMed

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
View in: PubMed

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. . 2010 Apr; 9(4):963-75.
View in: PubMed

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
View in: PubMed

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010 May; 149(4):550-9.
View in: PubMed

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
View in: PubMed

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
View in: PubMed

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9.
View in: PubMed

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
View in: PubMed

The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6.
View in: PubMed

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
View in: PubMed

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
View in: PubMed

Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
View in: PubMed

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
View in: PubMed

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010 May 20; 115(20):4051-60.
View in: PubMed

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 01; 16(3):1033-41.
View in: PubMed

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010 Jul; 95(7):1144-9.
View in: PubMed

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol. 2010 Jan; 62(1):145-51.
View in: PubMed

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in: PubMed

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34.
View in: PubMed

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
View in: PubMed

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52.
View in: PubMed

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010 Jan 28; 115(4):834-45.
View in: PubMed

Epigenetic modulation in hematologic malignancies: challenges and progress. J Natl Compr Canc Netw. 2009 Nov; 7 Suppl 8:S1-12; quiz S14-6.
View in: PubMed

From the guest editor: the evolving treatment paradigm in multiple myeloma. Cancer J. 2009 Nov-Dec; 15(6):456.
View in: PubMed

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
View in: PubMed

Hematology: Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol. 2009 Oct; 6(10):565-6.
View in: PubMed

NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42.
View in: PubMed

Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
View in: PubMed

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
View in: PubMed

Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res. 2009 Oct 01; 15(19):6035-41.
View in: PubMed

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
View in: PubMed

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009 Oct 01; 69(19):7577-86.
View in: PubMed

High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39.
View in: PubMed

Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
View in: PubMed

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2009 Nov; 147(4):531-4.
View in: PubMed

Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009 Sep 20; 27(27):4585-90.
View in: PubMed

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 2009 Sep 24; 114(13):2699-708.
View in: PubMed

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84.
View in: PubMed

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
View in: PubMed

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35.
View in: PubMed

What's Your Line? Clin Cancer Res. 2009 Jul 01; 15(13):4251.
View in: PubMed

Multiple myeloma. Lancet. 2009 Jul 25; 374(9686):324-39.
View in: PubMed

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
View in: PubMed

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009 Jun 15; 69(12):5082-90.
View in: PubMed

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
View in: PubMed

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23; 114(4):772-8.
View in: PubMed

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16; 114(3):619-29.
View in: PubMed

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52.
View in: PubMed

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9.
View in: PubMed

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
View in: PubMed

Maximizing the clinical benefit of novel therapies in multiple myeloma. Oncology (Williston Park). 2009 Apr 30; 23(5):415-6, 419.
View in: PubMed

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25; 113(26):6669-80.
View in: PubMed

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
View in: PubMed

Proteasome inhibitors in multiple myeloma. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S20-6.
View in: PubMed

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009 May; 41(5):521-3.
View in: PubMed

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36.
View in: PubMed

Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar; 14(1):99-127.
View in: PubMed

Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601.
View in: PubMed

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15; 15(4):1210-21.
View in: PubMed

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18.
View in: PubMed

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26; 113(13):3040-9.
View in: PubMed

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903.
View in: PubMed

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
View in: PubMed

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
View in: PubMed

Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):282-8.
View in: PubMed

Setting the standard for translational cancer research. Clin Cancer Res. 2009 Jan 01; 15(1):1.
View in: PubMed

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. . 2009 Jan; 8(1):26-35.
View in: PubMed

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402.
View in: PubMed

The current landscape of multiple myeloma treatment. Leuk Res. 2008 Dec; 32 Suppl 1:S1-24.
View in: PubMed

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21.
View in: PubMed

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008 Nov; 143(4):511-9.
View in: PubMed

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62.
View in: PubMed

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol. 2008 Nov; 143(4):520-31.
View in: PubMed

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22; 113(4):846-55.
View in: PubMed

Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008 Oct 21; 9 Suppl 1:S1.
View in: PubMed

Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14(10):1118-1124.
View in: PubMed

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15; 112(13):5095-102.
View in: PubMed

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40.
View in: PubMed

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
View in: PubMed

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28; 359(9):906-17.
View in: PubMed

Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7.
View in: PubMed

Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009 Feb; 45(2):164-72.
View in: PubMed

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
View in: PubMed

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008 Oct 10; 26(29):4784-90.
View in: PubMed

Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008 Aug 01; 14(15):4971-80.
View in: PubMed

Moving toward individualized cancer therapies. Clin Cancer Res. 2008 Aug 01; 14(15):4682-4.
View in: PubMed

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(1):46-53.
View in: PubMed

Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma. 2008 Jul; 49(7):1238-45.
View in: PubMed

MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol. 2008 Jul; 33(1):153-9.
View in: PubMed

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
View in: PubMed

Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
View in: PubMed

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2008 Jul; 4(7):973-85.
View in: PubMed

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
View in: PubMed

Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008 Jun 01; 26(16):2761-6.
View in: PubMed

Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer. 2008 Apr 15; 122(8):1879-84.
View in: PubMed

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
View in: PubMed

Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008 May; 141(5):659-71.
View in: PubMed

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May; 141(5):598-606.
View in: PubMed

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
View in: PubMed

Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
View in: PubMed

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63.
View in: PubMed

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7.
View in: PubMed

Re: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2008 Mar 05; 100(5):373.
View in: PubMed

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
View in: PubMed

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008 Feb; 118(2):491-504.
View in: PubMed

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008 Feb; 4(1):129-36.
View in: PubMed

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
View in: PubMed

Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol. 2008; 615:251-60.
View in: PubMed

The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007 Dec; 20(4):597-612.
View in: PubMed

Mouse models of human myeloma. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1051-69, viii.
View in: PubMed

From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):797-816.
View in: PubMed

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii.
View in: PubMed

Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1071-91, viii-ix.
View in: PubMed

Multiple myeloma. Preface. Hematol Oncol Clin North Am. 2007 Dec; 21(6):xiii-xiv.
View in: PubMed

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64.
View in: PubMed

Novel therapies in myeloma. Curr Opin Hematol. 2007 Nov; 14(6):609-15.
View in: PubMed

Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9.
View in: PubMed

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13(20):6162-7.
View in: PubMed

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9.
View in: PubMed

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs. 2007 Oct; 16(10):1693-707.
View in: PubMed

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63.
View in: PubMed

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
View in: PubMed

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
View in: PubMed

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
View in: PubMed

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
View in: PubMed

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 2007 Nov 15; 110(10):3744-52.
View in: PubMed

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60.
View in: PubMed

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; 7(8):585-98.
View in: PubMed

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46.
View in: PubMed

Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1474-8.
View in: PubMed

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.
View in: PubMed

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 01; 13(13):3771-5.
View in: PubMed

Introducing the clinical connection. Clin Cancer Res. 2007 Jul 01; 13(13):3761.
View in: PubMed

A strategic framework for novel drug development in multiple myeloma. Br J Haematol. 2007 Jul; 138(2):153-9.
View in: PubMed

Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7.
View in: PubMed

New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
View in: PubMed

Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
View in: PubMed

5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. . 2007 Jun; 6(6):1718-27.
View in: PubMed

Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
View in: PubMed

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 10; 25(17):2464-72.
View in: PubMed

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
View in: PubMed

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 01; 110(7):2561-4.
View in: PubMed

Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007 May 01; 104(18):7516-21.
View in: PubMed

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007 Jun; 137(5):429-35.
View in: PubMed

Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84.
View in: PubMed

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007 Apr 01; 109(7):2708-17.
View in: PubMed

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 2007 Apr; 35(4 Suppl 1):155-62.
View in: PubMed

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007 Apr; 11(4):349-60.
View in: PubMed

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2007 Apr; 7(4):551-66.
View in: PubMed

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood. 2007 Jul 15; 110(2):709-18.
View in: PubMed

Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
View in: PubMed

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. . 2007 Mar 01; 6(5):538-42.
View in: PubMed

Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007 Feb 15; 67(4):1680-8.
View in: PubMed

High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
View in: PubMed

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 01; 109(11):4964-72.
View in: PubMed

Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):118-47.
View in: PubMed

The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007 Feb; 5(2):149-62.
View in: PubMed

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
View in: PubMed

WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A. 2007 Jan 16; 104(3):926-31.
View in: PubMed

Inhibition of the TGF-beta signaling pathway in tumor cells. Recent Results Cancer Res. 2007; 172:77-97.
View in: PubMed

The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
View in: PubMed

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 Apr 15; 109(8):3177-88.
View in: PubMed

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol. 2007 Feb; 136(3):414-23.
View in: PubMed

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19478-83.
View in: PubMed

New frontiers in the treatment of multiple myeloma. ScientificWorldJournal. 2006 Dec 06; 6:1475-503.
View in: PubMed

Stem cell transplant for first relapse from the multiple myeloma research foundation. Oncology (Williston Park). 2006 Dec; 20(14):1818, 1820-1, 1825-6.
View in: PubMed

Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Dec; 47(12):2445-6.
View in: PubMed

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6826-35.
View in: PubMed

Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6603-10.
View in: PubMed

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
View in: PubMed

Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
View in: PubMed

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.
View in: PubMed

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77.
View in: PubMed

Recent advances in the treatment of Multiple Myeloma. Curr Pharm Biotechnol. 2006 Oct; 7(5):381-93.
View in: PubMed

Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006 Oct; 7(10):1341-7.
View in: PubMed

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94.
View in: PubMed

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1239-47.
View in: PubMed

Proteasome inhibitor drugs on the rise. Cancer Res. 2006 Aug 15; 66(16):7840-2.
View in: PubMed

New drugs for multiple myeloma. Clin Adv Hematol Oncol. 2006 Aug; 4(8):592-4.
View in: PubMed

Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006 Aug; 6(8):1165-73.
View in: PubMed

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
View in: PubMed

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56.
View in: PubMed

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
View in: PubMed

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol. 2006 Jul; 134(1):37-44.
View in: PubMed

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul; 91(7):929-34.
View in: PubMed

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10.
View in: PubMed

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006 Jun 15; 66(12):6379-86.
View in: PubMed

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.
View in: PubMed

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.
View in: PubMed

Time-domain frequency-selective processing in nuclear magnetic resonance: a spatial-spectral holographic perspective. J Opt Soc Am A Opt Image Sci Vis. 2006 Jun; 23(6):1391-9.
View in: PubMed

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9.
View in: PubMed

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May; 6(6):478-83.
View in: PubMed

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006 Apr; 9(4):313-25.
View in: PubMed

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9.
View in: PubMed

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704.
View in: PubMed

Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett. 2006 Feb 20; 233(1):10-5.
View in: PubMed

Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs. 2006 Feb; 15(2):171-9.
View in: PubMed

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006 Feb; 132(4):385-97.
View in: PubMed

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20; 24(6):929-36.
View in: PubMed

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62.
View in: PubMed

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 01; 66(1):184-91.
View in: PubMed

Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006; 57:33-47.
View in: PubMed

Velcade and vitamin C: too much of a good thing? Clin Cancer Res. 2006 Jan 01; 12(1):3-4.
View in: PubMed

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006 Jan 20; 24(3):334-6.
View in: PubMed

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
View in: PubMed

Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8530-3.
View in: PubMed

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15; 24(56):8259-67.
View in: PubMed

New treatments for multiple myeloma. Oncology (Williston Park). 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7.
View in: PubMed

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8.
View in: PubMed

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19.
View in: PubMed

Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.
View in: PubMed

Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol. 2005 Oct; 42(4 Suppl 4):S1-2.
View in: PubMed

Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct; 42(4 Suppl 4):S3-8.
View in: PubMed

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8.
View in: PubMed

Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50.
View in: PubMed

Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4.
View in: PubMed

Development of effective new treatments for multiple myeloma. J Clin Oncol. 2005 Oct 01; 23(28):7207-11.
View in: PubMed

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 01; 24(38):5888-96.
View in: PubMed

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005 Sep 01; 65(17):7896-901.
View in: PubMed

Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
View in: PubMed

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84.
View in: PubMed

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 01; 106(12):3777-84.
View in: PubMed

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81.
View in: PubMed

Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat. 2005 Aug; 8(4):205-18.
View in: PubMed

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
View in: PubMed

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16; 352(24):2487-98.
View in: PubMed

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8567-72.
View in: PubMed

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005 Jun 01; 11(11):4251-8.
View in: PubMed

Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700.
View in: PubMed

Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev Anticancer Ther. 2005 Jun; 5(3):465-76.
View in: PubMed

A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005 Aug 15; 106(4):1341-5.
View in: PubMed

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005 Sep 01; 106(5):1794-800.
View in: PubMed

Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol. 2005 May; 2(5):262-70.
View in: PubMed

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9.
View in: PubMed

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May; 2(5):357-62.
View in: PubMed

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 01; 106(3):1042-7.
View in: PubMed

A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005 Jul 15; 106(2):713-6.
View in: PubMed

Proteasome inhibitor therapy in multiple myeloma. . 2005 Apr; 4(4):686-92.
View in: PubMed

Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park). 2005 Apr; 19(4):447-50.
View in: PubMed

Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets. 2005 Apr; 9(2):359-81.
View in: PubMed

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12.
View in: PubMed

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200.
View in: PubMed

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6.
View in: PubMed

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
View in: PubMed

Proteasome inhibition in the treatment of cancer. . 2005 Feb; 4(2):290-6.
View in: PubMed

Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20; 23(3):630-9.
View in: PubMed

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 2005 Jan 20; 23(3):474-81.
View in: PubMed

Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005; 18(4):509-24.
View in: PubMed

Proteasome inhibitors as therapeutics. Essays Biochem. 2005; 41:205-18.
View in: PubMed

Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):619-34.
View in: PubMed

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
View in: PubMed

Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005; 45:465-76.
View in: PubMed

Clinical update: novel targets in multiple myeloma. Semin Oncol. 2004 Dec; 31(6 Suppl 16):27-32; discussion 33.
View in: PubMed

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
View in: PubMed

Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol. 2004 Dec; 31(6 Suppl 13):147-60.
View in: PubMed

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
View in: PubMed

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6.
View in: PubMed

Focus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44.
View in: PubMed

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6.
View in: PubMed

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005 Feb 15; 105(4):1383-95.
View in: PubMed

Mcl-1 regulation and its role in multiple myeloma. . 2004 Oct; 3(10):1259-62.
View in: PubMed

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 01; 105(1):350-7.
View in: PubMed

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 Sep 01; 10(17):5692-701.
View in: PubMed

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
View in: PubMed

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood. 2005 Mar 01; 105(5):2235-8.
View in: PubMed

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 01; 104(12):3688-96.
View in: PubMed

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol. 2004 Aug 15; 22(16):3212-4.
View in: PubMed

Novel immunomodulatory therapies in the treatment of multiple myeloma. Oncology (Williston Park). 2004 Jul; 18(8):988-90.
View in: PubMed

Multiple myeloma clinical practice guidelines in oncoloqy. J Natl Compr Canc Netw. 2004 Jul; 2(4):350-69.
View in: PubMed

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul; 79(7):875-82.
View in: PubMed

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004 Jul 01; 64(13):4629-36.
View in: PubMed

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66.
View in: PubMed

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004 Nov 01; 104(9):2886-92.
View in: PubMed

An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol. 2004 Jun; 5(3):227-38.
View in: PubMed

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
View in: PubMed

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene. 2004 Apr 29; 23(20):3597-602.
View in: PubMed

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
View in: PubMed

Advances in biology of multiple myeloma: clinical applications. Blood. 2004 Aug 01; 104(3):607-18.
View in: PubMed

TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes. Biochem Biophys Res Commun. 2004 Apr 02; 316(2):528-32.
View in: PubMed

Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004 May 14; 279(20):21658-65.
View in: PubMed

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar; 5(3):221-30.
View in: PubMed

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 Jan 15; 10(2):770-6.
View in: PubMed

Proteasome inhibition in hematologic malignancies. Ann Med. 2004; 36(4):304-14.
View in: PubMed

Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J. 2004; 5(1):9-23.
View in: PubMed

Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. . 2004 Jan; 3(1):39-45.
View in: PubMed

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5.
View in: PubMed

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
View in: PubMed

Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol. 2003 Dec; 123(5):869-78.
View in: PubMed

Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components. Transfusion. 2003 Dec; 43(12):1652-4.
View in: PubMed

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.
View in: PubMed

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene. 2003 Nov 27; 22(54):8797-801.
View in: PubMed

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004 May 01; 103(9):3474-9.
View in: PubMed

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.
View in: PubMed

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
View in: PubMed

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.
View in: PubMed

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003 Oct 01; 63(19):6174-7.
View in: PubMed

The role of immunomodulatory drugs in multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):23-32.
View in: PubMed

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 Oct 01; 63(19):6187-94.
View in: PubMed

Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol. 2003 Oct; 1(10):596-600.
View in: PubMed

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.
View in: PubMed

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300.
View in: PubMed

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8.
View in: PubMed

Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806.
View in: PubMed

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. . 2003 Sep; 2(9):825-33.
View in: PubMed

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003 Sep-Oct; 10(5):361-9.
View in: PubMed

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11.
View in: PubMed

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9946-51.
View in: PubMed

Novel therapeutic approaches for multiple myeloma. Immunol Rev. 2003 Aug; 194:164-76.
View in: PubMed

Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol. 2003 Aug; 78(2):114-20.
View in: PubMed

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86.
View in: PubMed

A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17.
View in: PubMed

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
View in: PubMed

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
View in: PubMed

Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol. 2003 Jun; 7(2):191-204.
View in: PubMed

Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003 May 15; 63(10):2561-8.
View in: PubMed

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6.
View in: PubMed

Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003 Aug 15; 102(4):1435-42.
View in: PubMed

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol. 2003 Apr; 30(2):156-60.
View in: PubMed

Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.
View in: PubMed

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
View in: PubMed

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003 Apr; 30(2):248-52.
View in: PubMed

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003 Apr; 31(4):271-82.
View in: PubMed

JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6.
View in: PubMed

New agents and approaches in the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2003 Mar; 1(3):151-2.
View in: PubMed

Moving disease biology from the lab to the clinic. Cancer. 2003 Feb 01; 97(3 Suppl):796-801.
View in: PubMed

Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
View in: PubMed

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
View in: PubMed

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003 Jan; 9(1):4-37.
View in: PubMed

Novel therapies for multiple myeloma. Br J Haematol. 2003 Jan; 120(1):10-7.
View in: PubMed

Multiple myeloma: how far have we come? Mayo Clin Proc. 2003 Jan; 78(1):15-7.
View in: PubMed

The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. Biochem Biophys Res Commun. 2002 Dec 13; 299(4):532-8.
View in: PubMed

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.
View in: PubMed

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801.
View in: PubMed

Moving disease biology from the laboratory to the clinic. Semin Oncol. 2002 Dec; 29(6 Suppl 17):17-20.
View in: PubMed

Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002 Dec; 2(12):927-37.
View in: PubMed

Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. . 2002 Dec; 1(14):1361-5.
View in: PubMed

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9.
View in: PubMed

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
View in: PubMed

Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol. 2002 Nov; 14(6):635-40.
View in: PubMed

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7.
View in: PubMed

Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
View in: PubMed

Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion. 2002 Oct; 42(10):1279-84.
View in: PubMed

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4.
View in: PubMed

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94.
View in: PubMed

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5.
View in: PubMed

Novel biologically based therapeutic strategies in myeloma. Rev Clin Exp Hematol. 2002 Sep; 6(3):301-24.
View in: PubMed

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
View in: PubMed

Novel therapies for multiple myeloma. Blood Rev. 2002 Sep; 16(3):167-74.
View in: PubMed

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000.
View in: PubMed

Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents. 2002 Sep; 2(5):567-75.
View in: PubMed

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002 Sep 01; 20(17):3719-36.
View in: PubMed

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
View in: PubMed

Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1.
View in: PubMed

Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. . 2002 Aug; 1(10):851-60.
View in: PubMed

Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. Blood. 2002 Jul 15; 100(2):698-700.
View in: PubMed

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20.
View in: PubMed

Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82.
View in: PubMed

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
View in: PubMed

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
View in: PubMed

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
View in: PubMed

What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Crit Rev Oncol Hematol. 2002 May; 42(2):163-71.
View in: PubMed

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. . 2002 May; 1(7):539-44.
View in: PubMed

Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett. 2002 Apr 25; 178(2):187-97.
View in: PubMed

S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002 Apr 15; 62(8):2300-5.
View in: PubMed

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002 Apr 01; 99(7):2512-7.
View in: PubMed

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002 Mar 15; 99(6):2162-71.
View in: PubMed

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. Exp Hematol. 2002 Mar; 30(3):212-20.
View in: PubMed

NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.
View in: PubMed

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58.
View in: PubMed

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood. 2002 Feb 15; 99(4):1419-27.
View in: PubMed

Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J. 2002 Jan-Feb; 8(1):12-25.
View in: PubMed

Multiple myeloma. Hematology Am Soc Hematol Educ Program. 2002; 214-40.
View in: PubMed

Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002; 53:629-57.
View in: PubMed

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002 Jan-Feb; 25(1):72-81.
View in: PubMed

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002 Mar 08; 277(10):7875-81.
View in: PubMed

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother (1991). 2001 May; 24(3):263-271.
View in: PubMed

Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am Soc Hematol Educ Program. 2000; 147-165.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Mayer 557
Boston, MA 02215
Get Directions

Ratings

Top